Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
66
resultados
Última actualización
04/10/2026 [06:45:00]
Resumen de: US20260297147A1
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector including the nucleic acid molecule, a host cell including the expression vector or the genome integrated with the nucleic acid molecule, a preparation method therefor and a pharmaceutical composition thereof. Further provided is the use of the above-mentioned product, such as keratin YK93-2 in the preparation of a drug for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroid, prostatic hyperplasia etc.
Resumen de: US20260294848A1
0000 The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Resumen de: US20260297156A1
0000 The present invention relates to the field of immunotherapy, in particular, adoptive T cell therapy of MAGEA1-associated cancer. TCR alpha chain constructs (TRA) and/or a TCR beta chain constructs (TRB) of TCR constructs specific for an epitope in complex with a human MHC-I, wherein the epitope is an epitope of a MAGEA1 protein, nucleic acids encoding them and host cells expressing them. The invention also provides pharmaceutical compositions or kits based theron. The invention teaches combinations of TCR constructs directed to different epitopes from the same antigen expressed by the same cancer or infectious agent capabel of being presented by different MHC-I molecules, wherein optionally, the antigen is MAGEA1. Preferably, at least one of the TCR constructs used in the combination is a TCR construct of the invention disclosed herein. The pharmaceutical combinations or kits may be used for immunotherapy of a subject, e.g., adoptive T cell therapy or TCR gene therapy, e.g., for use in treatment of a cancer such as lung cancer, colorectal cancer, or multiple myeloma. The invention also provides peptides comprising the epitopes recognized by the TCR constructs of the invention, which may be for use in vaccination, e.g., peptide vaccination or RNA vaccination.
Resumen de: US20260295033A1
An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.
Resumen de: US20260297031A1
0000 In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit breakpoint cluster region, chromosome 22 (BCR) and Abelson proto-oncogene 1, chromosome 9 (ABL1) in a subject, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant BCR and ABL1 activity. In another aspect, the compounds described herein can evade P-gp-mediated efflux in a subject, which makes the compounds effective in treating a Philadelphia chromosome positive (Ph+) leukemia.
Resumen de: US20260294951A1
0000 The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and/or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.
Resumen de: US20260297148A1
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a preparation method for the keratin YK93-5, and a pharmaceutical composition of the keratin YK93-5, and further provides a use of the products such as the keratin YK93-5 in the preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroids, prostatic hyperplasia, etc.
Resumen de: US20260294921A1
0000 The present application discloses specific compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and their use in therapy, in particular, their use as human polymerase theta (Polθ) inhibitors for the treatment of hyperproliferative diseases including cancers such as carcinoma, sarcoma, adenocarcinoma, leukemia, lymphoma, and melanoma, and pre-malignant conditions. The application further discloses the use of a compound of formula (I), in combination with an additional anticancer therapy.
0000
Resumen de: EP4813396A2
Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
Resumen de: EP4813380A1
The present invention relates to the use of the alkyl phospholipid edelfosine (especially (S)-edelfosine) in the treatment of multiple myeloma.
Resumen de: WO2025108429A1
A chimeric antigen receptors (CARs) and CAR-NK cells targeting both BCMA and GPRC5D and use thereof in treating multiple myeloma (MM) is provided. In particular, the disclosure relates to bi-specific CARs comprising: (a) a B-cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor of family C, group 5, member D (GPRC5D) targeting domain, preferably armored with such as IL15, and the corresponding coding polynucleotides for the CARs and vectors comprising the polynucleotides. Also provided is CAR-NK cell modified with the CAR (s), and use of the CAR and CAR-NK cell in the treatment of MM.
Resumen de: WO2026198634A1
The invention provides an invariant natural killer T (iNKT) cell-targeted microparticle recruitment and activation system (iMRAS), one which provides a biomimetic platform that enhances iNKT cell functionality through localized immunostimulation in vivo. This biomimetic platform is designed to function as an in vivo "charging station" containing chemotactic and activation signals for the recruitment, activation, and expansion of CAR-iNKT cells, leading to more effective tumor killing and longer persistence of CAR-iNKT cells, as demonstrated in lymphoma and melanoma. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumors, establishing a robust platform for enhancing systemic CAR-iNKT cell-mediated immunotherapy.
Resumen de: WO2026198571A1
The present disclosure concerns methods and compositions related to sdAbs targeting cyclin. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of cyclin is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of acute myeloid leukemia and other cancers that express cyclin.
Resumen de: AU2026220660A1
The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.
Resumen de: AU2025255746A1
The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).
Resumen de: US20260284185A1
Problem A composition and a method that can be used to induce an immune response to HTLV-1 are required.Solution A lipid complex comprising at least one nucleic acid selected from: a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of human T-cell leukemia virus 1 (HTLV-1) antigenic Gag protein; a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic Tax protein; and a nucleic acid comprising a polynucleotide that encodes an immunogenic fragment of HTLV-1 antigenic HBZ protein; wherein the at least one nucleic acid is encapsulated in a lipid.
Resumen de: US20260286305A1
The present invention relates to recombinant CAR-NK cells or CAR T-cells, expressing a CAR binding to the antigen CLEC12A or a functional alternatively spliced transcript variant thereof, wherein at least one immune checkpoint receptor protein, such as, for example NKG2A, CLEC12A, PD-1, TIM-3, TIGIT and/or KIRS, is inactivated. These highly functional immune check-point-inactivated CAR-NK cells or CAR T-cells target cancer-associated antigens or are adapted for a treatment of autoimmune diseases. Furthermore, the present invention relates to a non-virus-based method for producing a CAR-NK cell or CAR T-cell expressing an antigen-targeting chimeric antigen receptor (CAR) and a recombinant CAR-NK cell or CAR T-cell as produced, in particular a CAR-NK cell or CAR T-cell targeting the cancer-associated antigen CLEC12A. The present invention also relates to medical uses of the CAR-NK cell or CAR T-cell. The present invention further relates to a CAR-construct, comprising a modified CD8α or CD28
Resumen de: US20260284190A1
0000 The present invention relates to the combination of anti-CD3 agent, in particular monoclonal antibody, with immunotherapeutic agents, and its use in oncology, for treating T Cell Acute Lymphoblastic Leukemia (T-ALL). The invention also relates to a pharmaceutical composition comprising said combination and the use of said combination to induce cell death of T-ALL cells.
Resumen de: US20260286007A1
0000 Aspects of the disclosure provide anti-TMPRSS6 antibodies and methods of using the same for promoting hepcidin expression, and treating iron overload associated conditions, such as hemochromatosis, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), blood transfusion.
Resumen de: US20260284212A1
0000 Provided herein are human Cluster of Differentiation 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are human CD6 binding molecules (e.g., nanobodies) having a first, and optionally a second, single monomeric variable antibody domain (SMVAD) that comprises certain CDRs, and methods for using such molecules to treat T-cell related diseases (e.g., cancer, such as T-cell lymphoma). In certain embodiments, the SMVAD comprises camelid, human, or humanized framework regions.
Resumen de: US20260285879A1
0000 Provided is compound A or a pharmaceutically acceptable salt thereof in a crystalline form. The structure of compound A is represented by formula (I) below. Studies have shown that a crystalline form A-1 of the free base of compound A, crystalline form B of a hydrochloride salt of compound A and crystalline form C of a benzenesulfonate salt of compound A have certain physical stability and chemical stability. The compound A or the pharmaceutically acceptable salt thereof in a crystalline form can significantly inhibit the proliferation of various cells of tumors such as breast cancer, colorectal cancer, ovarian cancer, melanoma, liver cancer, lung cancer and acute myeloid leukemia; and also has a good inhibitory effect on palbociclib-resistant (including primary drug resistance and acquired drug resistance) breast cancer and liver cancer. Therefore, the compound A or the pharmaceutically acceptable salt thereof in a crystalline form has good clinical application prospects in the treatment of advanced malignant tumors, and provides a new drug choice for the treatment of CDK4/6 inhibitor-resistant tumors.
0000
Resumen de: US20260285973A1
0000 The present technology aims at providing a novel type of drug for treating a subject suffering from acute myeloid leukemia (AML). Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVDs binds to T cell receptor αβ (TCRαβ), at least ISVD binds to CD33, and at least one ISVD binds to CD123. The present technology also provides nucleic acids, vectors and compositions.
Resumen de: WO2026195138A1
The inventions relate to the field of medicine and pharmaceutics, and more particularly to new protein kinase B inhibitor compounds and methods of producing and using same to treat myeloid leukemia and/or myelodysplastic syndrome. The inventions provide for the clinical effectiveness of immune pathway inhibitors, improved immune control, and suppression of the expression of a number of immune checkpoint molecules, including PD-1L, TIM-3, TIGIT, CD155, CD200 and VISTA, simultaneously on the surface of leukemia cells, which creates the prerequisites for an increase in the rate and duration of remission and an increase in patient survival rates. Through the development of intracellular signalling pathway inhibitors which have the pharmacological effect of suppressing the expression of a number of immune checkpoint molecules on the surface of tumour cells, the inventions widen the range of agents that can be used for treating myeloid leukemia and myelodysplastic syndromes.
Resumen de: WO2026198804A1
Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. Some embodiments relate to methods of treating, preventing, or ameliorating relapsed or refractory classical Hodgkin's lymphoma in a subject. In some embodiments, the method includes administering plinabulin to a subject in need thereof, wherein the Hodgkin's lymphoma has progressed following autologous or allogeneic stem cell transplantation and has demonstrated resistance to one or more immune checkpoint inhibitors. In certain embodiments, the method further includes co-administering an immune checkpoint inhibitor, such as a PD-1 or PD-L1 inhibitor, and optionally radiation therapy or a chemotherapeutic agent. In some embodiments, the disclosed methods result in re-sensitization to immune checkpoint inhibitors and provide durable clinical responses in subjects with limited remaining treatment options.
Nº publicación: WO2026198551A1 24/09/2026
Solicitante:
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Resumen de: WO2026198551A1
The present disclosure concerns methods and compositions related to sdAbs targeting GPRC5D and FCRH5. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of GPRC5D or FCRH5 is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of multiple myeloma (MM) and/or B-cell lymphoproliferative disorders and other cancers that express GPRC5D or FCRH5.
BOPI
Sede Electrónica
